Merck plans to set up 100% subsidiary in India

Chemical Weekly Group

首页> 外文期刊>Chemical Weekly >Merck plans to set up 100% subsidiary in India

【24h】

Merck plans to set up 100% subsidiary in India

机译：默克计划在印度设立100％子公司

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

German drug major Merck KGaA plans to set up a 100% subsidiary in India.In a statement received by the BSE,Merck KGaA wholly owned subsidiary Merck Holding GmbH has submitted an application to the Foreign Investment Promotion Board(FIPB)to set up a subsidiary in the country.Merck KGaA,Germany,through their affiliates holds 51 % of the share capital of Merck in India.

机译：德国药品巨头默克公司计划在印度设立100％的子公司。在BSE收到的一份声明中，默克公司的全资子公司默克公司已向外国投资促进委员会（FIPB）提出了设立子公司的申请。在德国。MerckKGaA通过其关联公司持有默克在印度的51％的股本。

著录项

来源
《Chemical Weekly》 |2005年第31期|共1页
作者
Chemical Weekly Group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Merck plans to set up 100% subsidiary in India [J] . Chemical Weekly Group Chemical Weekly . 2005,第31期

机译：默克计划在印度设立100％子公司
2. OG Corp sets up 100% subsidiary company; pointer to greater engagement in Indian market [J] . Chemical Weekly Group Chemical Weekly . 2014,第30期

机译：OG Corp成立100％子公司;扩大印度市场参与度的指针
3. NORD sets up 100% subsidiary in India [J] . Chemical Engineering World Group Chemical Engineering World . 2007,第4期

机译：NORD在印度设立100％子公司
4. AN EXAMINATION OF IS PLANNING AUTONOMY AND IS PLANNING EFFECTIVENESS IN U.S. SUBSIDIARIES OF FOREIGN FIRMS [C] . Dinesh A. Mirchandani, Albert L. Lederer 33rd Annual meeting of the Decision Sciences Institute . 2002

机译：美国外国公司子公司的IS计划自治性和计划效力的检验
5. Challenges and Strategies for Offshoring R&D to Emerging Countries: Evidence from Foreign MNCs R&D Subsidiaries in India [D] . Borah, Dhruba Jyoti. 2019

机译：新兴国家离岸研发的挑战与策略：印度外国MNCS研发子公司的证据
6. Hidden duplicates: 10s or 100s of Indian trials registered with ClinicalTrials.gov have not been registered in India as required by law [O] . Sangeeta Kumari, Abhilash Mohan, Gayatri Saberwal, 2020

机译：隐藏的复制品：10年代或100岁的印度试验注册为Clinicaltrials.gov尚未在法律要求中在印度注册
7. Effect of Cyclophosphoramide, 6-Mercaptopurine, Actinomycin D and Vincaleukoblastine on the Acquisition of Delayed Hypersensitivity (DNCB Contact Dermatitis) in the Guinea-Pig11From the Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia 4, Pennsylvania.This study was supported in part by U.S.P.H.S. Training Grant 2 G-62.This investigation was carried out during the tenure of a postdoctoral fellowship, held by Dr. Maibach, from the Division of General Medical Sciences, United States Public Health Service.Cyclophosphoramide (Cytoxan®) was supplied by Paul A. Walter, M.D., Mead Johnson Laboratories, Evansville 21, Indiana; 6-mercaptopurine by Donald S. Searle, M.D., Burroughs Wellcome Co., Tuckahoe, N.Y.; vincaleukoblastine by J. A. Armstrong, M.D., Eli Lilly and Co., Indianapolis 6, Indiana; and Actinomycin D by Elmer Alpert, M.D., Merck Sharp and Dohme, West Point, Pa.Presented at the Twenty-second Annual Meeting of The Society for Investigative Dermatology, Inc., New York, N.Y., June 28, 1961. [O] . Maguire Henry C., Maibach Howard I. 1961

机译：几内亚-Pig11的环磷酰胺，6-巯基嘌呤，放线菌素D和Vincaleukoblastine对迟发型超敏反应（DNCB接触性皮炎）习得的影响宾夕法尼亚州宾夕法尼亚大学医学院皮肤病学系，宾夕法尼亚州费城4 USPHS的一部分培训补助金2 G-62。这项研究是在美国公共卫生服务部普通医学科的迈巴赫博士担任博士后研究金期间进行的，环磷酰胺（Cytoxan®）由Paul A提供美国印第安纳州埃文斯维尔21号米德·约翰逊实验室的Walter医师；纽约州塔克霍市Burroughs Wellcome＆Co.的Donald S.Searle，M.D.的6-巯基嘌呤; vincaleukoblastine，J。A. Armstrong，医学博士，礼来公司，印第安纳州印第安纳波利斯6；和放线菌素D由宾夕法尼亚州西点的默克·夏普（Merck Sharp）和多梅（Merck Sharp and Dohme）于1961年6月28日在纽约州纽约市研究皮肤病学会举行第二十二届年会上发表。

Merck plans to set up 100% subsidiary in India

摘要

著录项

相似文献

相关主题

期刊订阅